#USA #Toronto #Clinical Trials #biorepository #Resonant Clinical Solutions

Resonant Clinical Solutions: A New Era in Sample Management

In a bold move to address the growing complexities of clinical trials, Resonant Clinical Solutions has launched a suite of asset management programs aimed at enhancing sample storage strategies for life sciences organizations. The newly introduced programs, namely Remote Asset Management (RAM), Proactive Asset Management (PAM), and Strategic Asset Management (SAM), were unveiled at the ISBER 2026 International Biospecimen Summit held simultaneously in Toronto. This initiative marks a pivotal step towards modernizing the handling and management of biorepositories associated with clinical studies.

Understanding the Growing Complexity

The world of life sciences is evolving rapidly. Companies are now tasked with managing larger volumes of samples than ever before, often spread across multiple sites and in various contractual research organizations (CROs). As clinical programs adopt more complex methodologies, such as cell and gene therapies, the requirements for data integrity, traceability, and audit readiness become increasingly stringent. Simultaneously, the scarcity of laboratory space and the rising costs associated with sample management have made critical decision-making regarding sample storage more essential than ever.

Christophe Berthoux, CEO of Resonant Clinical Solutions, emphasized the importance of these decisions, stating, "Research samples represent years of investment and, in many cases, irreplaceable scientific insights. Yet, decisions regarding them are often made out of necessity rather than through careful consideration." This sentiment underscores the need for systematic approaches to sample asset management, which the three newly introduced programs aim to provide.

Tailored Programs for Diverse Needs

Each program begins with a detailed assessment of the client's inventory and requirements, addressing various scenarios:

1. Remote Asset Management (RAM): Targeted at organizations that house samples in their own laboratories or freezers, RAM aims to free up valuable research time and space. Resonant dispatches biorepository specialists to evaluate existing inventory and operational requirements while ensuring compliance with regulations. Real-time digital cataloging provides full transparency and optimized sample utilization, crucial for enhanced efficiency.

2. Proactive Asset Management (PAM): Designed for organizations whose studies are finished but have samples still dispersed across different locations, PAM facilitates the consolidation of these samples. The Resonant team manages the communication with partner laboratories and CROs, effectively coordinating logistics to transport samples to Resonant’s secure long-term biorepository, thus maintaining a validated inventory for future reference.

3. Strategic Asset Management (SAM): Aimed at entities contemplating changes in storage practices, SAM analyzes inventory and storage costs to provide a comprehensive breakdown of alternatives. This program assists clients in navigating the complexities of insourcing solutions or transferring samples to different vendors, enabling informed decision-making that aligns with both financial and operational objectives.

Corey Stone, Vice President and General Manager of Biorepository at Resonant, noted, "We developed this program series to offer tailored solutions that address varying customer needs. We identify which program best fits a customer’s current situation and provide the necessary infrastructure and regulatory expertise to deliver optimal solutions that enhance reliability, efficiency, and value."

Availability and Future Directions

All three asset management programs are now available for life science organizations seeking to navigate the complexities of sample management in clinical trials. These initiatives reflect Resonant's commitment to support its clients throughout the clinical supply chain, helping them focus on scientific advancements and patient outcomes.

For further information, visit Resonant Clinical Solutions or reach out via email at [email protected]. Resonant is also exhibiting at the ISBER 2026 International Biospecimen Summit at Booth No. 14, providing an opportunity for further engagement and exploration of these innovative solutions.

As life science companies continue to evolve, Resonant Clinical Solutions stands ready to meet their challenges with cutting-edge asset management strategies, ensuring they remain at the forefront of the clinical landscape.